These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 1831952)
21. How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity. Ebashi M; Ito Y; Uematsu M; Nakamura A; Hirokawa K; Kamei S; Uchihara T Acta Neuropathol Commun; 2019 May; 7(1):71. PubMed ID: 31060611 [TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. Flament S; Delacourte A; Mann DM Brain Res; 1990 May; 516(1):15-9. PubMed ID: 2142011 [TBL] [Abstract][Full Text] [Related]
23. Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. Berry RW; Sweet AP; Clark FA; Lagalwar S; Lapin BR; Wang T; Topgi S; Guillozet-Bongaarts AL; Cochran EJ; Bigio EH; Binder LI J Neurocytol; 2004 May; 33(3):287-95. PubMed ID: 15475684 [TBL] [Abstract][Full Text] [Related]
24. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Joachim CL; Morris JH; Kosik KS; Selkoe DJ Ann Neurol; 1987 Oct; 22(4):514-20. PubMed ID: 2963585 [TBL] [Abstract][Full Text] [Related]
25. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Scaravilli T; Tolosa E; Ferrer I Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076 [TBL] [Abstract][Full Text] [Related]
26. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854 [TBL] [Abstract][Full Text] [Related]
27. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. Puangmalai N; Bhatt N; Montalbano M; Sengupta U; Gaikwad S; Ventura F; McAllen S; Ellsworth A; Garcia S; Kayed R Cell Death Dis; 2020 May; 11(5):314. PubMed ID: 32366836 [TBL] [Abstract][Full Text] [Related]
28. Characterization of two pathological tau protein, variants in Alzheimer brain cortices. Flament S; Delacourte A; Hémon B; Défossez A J Neurol Sci; 1989 Sep; 92(2-3):133-41. PubMed ID: 2509637 [TBL] [Abstract][Full Text] [Related]
29. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231 [TBL] [Abstract][Full Text] [Related]
30. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Chambers CB; Lee JM; Troncoso JC; Reich S; Muma NA Ann Neurol; 1999 Sep; 46(3):325-32. PubMed ID: 10482263 [TBL] [Abstract][Full Text] [Related]
31. Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration. Delacourte A Biomed Pharmacother; 1994; 48(7):287-95. PubMed ID: 7858159 [TBL] [Abstract][Full Text] [Related]
32. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765 [TBL] [Abstract][Full Text] [Related]
34. Neurofibrillary degeneration and microtubule associated protein tau. Yen SH; Liu WK Chin J Physiol; 1992; 35(4):357-66. PubMed ID: 1308732 [TBL] [Abstract][Full Text] [Related]
35. Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Dugger BN; Tu M; Murray ME; Dickson DW Neurosci Lett; 2011 Mar; 491(2):122-6. PubMed ID: 21236314 [TBL] [Abstract][Full Text] [Related]
36. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. Ferrer I; Blanco R; Carmona M; Puig B J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404 [TBL] [Abstract][Full Text] [Related]
37. Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Tabaton M; Whitehouse PJ; Perry G; Davies P; Autilio-Gambetti L; Gambetti P Ann Neurol; 1988 Sep; 24(3):407-13. PubMed ID: 3067653 [TBL] [Abstract][Full Text] [Related]
38. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Padmanabhan J; Levy M; Dickson DW; Potter H Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932 [TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. Mailliot C; Sergeant N; Bussière T; Caillet-Boudin ML; Delacourte A; Buée L FEBS Lett; 1998 Aug; 433(3):201-4. PubMed ID: 9744794 [TBL] [Abstract][Full Text] [Related]